Clinical Trial Update: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis [Phase 2, Phase 3]

View source ↗

Summary

The Phase 2/Phase 3 trial evaluating belapectin for the prevention of esophageal varices in NASH-related cirrhosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Esophageal Varices
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Belapectin (belapectin)

Snippet

Sponsor: Galectin Therapeutics Inc. | Conditions: Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis | Phase 2, Phase 3 | Status: TERMINATED